Published in In Vivo on May 20, 2009
Environmental chemical exposures and human epigenetics. Int J Epidemiol (2011) 1.97
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int (2011) 1.19
Epigenetic susceptibility factors for prostate cancer with aging. Prostate (2013) 0.94
The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters. BMC Cancer (2014) 0.83
Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol (2013) 0.82
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]. Ann Pathol (2011) 1.44
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res (2005) 1.25
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A (2002) 1.23
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Spectrum of PTCH1 mutations in French patients with Gorlin syndrome. J Invest Dermatol (2003) 1.16
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Werner syndrome and mutations of the WRN and LMNA genes in France. Hum Mutat (2006) 1.07
Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer (2003) 1.06
DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res (2008) 1.06
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther (2009) 1.05
Molecular insights on basal-like breast cancer. Breast Cancer Res Treat (2012) 1.05
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci (2012) 1.04
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon. Hered Cancer Clin Pract (2012) 1.00
BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci (2008) 1.00
Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol (2011) 0.98
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol (2002) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case-control study from Central and Eastern Europe. Occup Environ Med (2011) 0.98
Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J Mol Diagn (2012) 0.97
CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res (2011) 0.97
BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol (2012) 0.97
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo (2010) 0.96
Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics (2014) 0.95
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep (2011) 0.95
Central adiposity as a major risk factor of ovarian cancer. Anticancer Res (2009) 0.93
Epigenetic modifications in prostate cancer. Epigenomics (2014) 0.93
Psychopathological features of a patient population of targets of workplace bullying. Occup Med (Lond) (2008) 0.92
Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo (2009) 0.91
Revascularization of traumatic renal artery dissection by endoluminal stenting: three cases. Acta Radiol (2010) 0.91
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int J Cancer (2005) 0.91
Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'. Arthritis Res Ther (2013) 0.91
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat (2010) 0.91
Oncological risk of laparoscopic surgery in urothelial carcinomas. World J Urol (2008) 0.90
Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res (2009) 0.89
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families. Oncogene (2002) 0.89
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One (2011) 0.88
The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease. Nat Med (2003) 0.88
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. Br J Nutr (2002) 0.87
Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach. OMICS (2010) 0.87
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev (2005) 0.86
Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation (2003) 0.86
Evaluation of breast cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen metabolisms. Nutr Cancer (2010) 0.86
Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target genes of cancer prostatic cells. Am J Clin Nutr (2010) 0.86
DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer (2008) 0.86
DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics (2011) 0.86
Histopathologic and ultrastructural features and claudin expression in papillary tumors of the pineal region: a multicenter analysis. Am J Surg Pathol (2012) 0.86
miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo (2011) 0.86
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats. Cancer Res (2003) 0.85
Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clin Chim Acta (2011) 0.85
Outcome and cost analysis of sacral nerve modulation for treating urinary and/or fecal incontinence. Ann Surg (2011) 0.84
Effects of the phytoestrogens genistein and daidzein on BRCA2 tumor suppressor gene expression in breast cell lines. Nutr Cancer (2003) 0.84
Leptin induces a proliferative response in breast cancer cells but not in normal breast cells. Nutr Cancer (2014) 0.84
[Epidemiology of and risk factors for bladder cancer and for urothelial tumors]. Rev Prat (2014) 0.84
A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA. World J Urol (2012) 0.83
Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR. J Histochem Cytochem (2007) 0.83
The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters. BMC Cancer (2014) 0.83